These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 9525341

  • 21. Isolation and characterization of two disintegrins inhibiting ADP-induced human platelet aggregation from the venom of Crotalus scutulatus scutulatus (Mohave Rattlesnake).
    Sánchez EE, Galán JA, Russell WK, Soto JG, Russell DH, Pérez JC.
    Toxicol Appl Pharmacol; 2006 Apr 01; 212(1):59-68. PubMed ID: 16084550
    [Abstract] [Full Text] [Related]

  • 22. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells.
    Shahan TA, Ziaie Z, Pasco S, Fawzi A, Bellon G, Monboisse JC, Kefalides NA.
    Cancer Res; 1999 Sep 15; 59(18):4584-90. PubMed ID: 10493512
    [Abstract] [Full Text] [Related]

  • 23. Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression.
    Zhou Q, Sherwin RP, Parrish C, Richters V, Groshen SG, Tsao-Wei D, Markland FS.
    Breast Cancer Res Treat; 2000 Jun 15; 61(3):249-60. PubMed ID: 10966001
    [Abstract] [Full Text] [Related]

  • 24. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nickols GA.
    Cancer Res; 1998 May 01; 58(9):1930-5. PubMed ID: 9581835
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Leberagin-C, A disintegrin-like/cysteine-rich protein from Macrovipera lebetina transmediterranea venom, inhibits alphavbeta3 integrin-mediated cell adhesion.
    Limam I, Bazaa A, Srairi-Abid N, Taboubi S, Jebali J, Zouari-Kessentini R, Kallech-Ziri O, Mejdoub H, Hammami A, El Ayeb M, Luis J, Marrakchi N.
    Matrix Biol; 2010 Mar 01; 29(2):117-26. PubMed ID: 19808093
    [Abstract] [Full Text] [Related]

  • 29. Effects of kistrin on bone resorption in vitro and serum calcium in vivo.
    King KL, D'Anza JJ, Bodary S, Pitti R, Siegel M, Lazarus RA, Dennis MS, Hammonds RG, Kukreja SC.
    J Bone Miner Res; 1994 Mar 01; 9(3):381-7. PubMed ID: 8191932
    [Abstract] [Full Text] [Related]

  • 30. Structure-activity studies of the s-echistatin inhibition of bone resorption.
    Sato M, Garsky V, Majeska RJ, Einhorn TA, Murray J, Tashjian AH, Gould RJ.
    J Bone Miner Res; 1994 Sep 01; 9(9):1441-9. PubMed ID: 7817829
    [Abstract] [Full Text] [Related]

  • 31. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
    Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA.
    J Endocrinol; 2000 Jun 01; 165(3):587-98. PubMed ID: 10828842
    [Abstract] [Full Text] [Related]

  • 32. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.
    Horton MA, Taylor ML, Arnett TR, Helfrich MH.
    Exp Cell Res; 1991 Aug 01; 195(2):368-75. PubMed ID: 1712731
    [Abstract] [Full Text] [Related]

  • 33. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor.
    Jones JI, Prevette T, Gockerman A, Clemmons DR.
    Proc Natl Acad Sci U S A; 1996 Mar 19; 93(6):2482-7. PubMed ID: 8637900
    [Abstract] [Full Text] [Related]

  • 34. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis.
    Dresner-Pollak R, Rosenblatt M.
    J Cell Biochem; 1994 Nov 19; 56(3):323-30. PubMed ID: 7876325
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.
    Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M.
    Endocrinology; 1993 Mar 19; 132(3):1411-3. PubMed ID: 8440195
    [Abstract] [Full Text] [Related]

  • 38. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro.
    Gramoun A, Shorey S, Bashutski JD, Dixon SJ, Sims SM, Heersche JN, Manolson MF.
    J Cell Biochem; 2007 Oct 01; 102(2):341-52. PubMed ID: 17390341
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.